Implantation of Markers for the Radiotherapy of Lung Cancer Patients
- Conditions
- Lung Cancer
- Interventions
- Radiation: radiation therapy treatment planning/simulationProcedure: implanted fiducial-based imaging
- Registration Number
- NCT00856427
- Lead Sponsor
- Virginia Commonwealth University
- Brief Summary
This clinical trial studies imaging markers in planning radiation therapy in patients with lung cancer. Implanting markers in the tumor that can be seen using imaging procedures during radiation therapy may allow x-rays to be sent directly to the tumor and cause less damage to normal tissue.
- Detailed Description
OBJECTIVES:
* To acquire experience in the marker implantation process for mediastinal lymph nodes and primary lung tumors in patients with stage I-IIIB non-small cell lung cancer.
* To characterize the potential side effects involved in the use of markers in these patients.
* To analyze the positional stability of lung markers in these patients over a radiotherapy series.
* To acquire experience in the use of markers for treatment planning and radiotherapy in these patients.
OUTLINE: Patients undergo implantation of ≥ 1 small radio-opaque Visicoil™ marker into or close to the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo x-rays to document marker location, detect potentially dropped markers, and diagnose operation-related side effects (i.e., pneumothorax). After marker implantation, patients undergo stereotactic or conventionally fractionated radiotherapy for 30-33 daily fractions.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Diagnostic radiation therapy treatment planning/simulation Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors). Diagnostic implanted fiducial-based imaging Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
- Primary Outcome Measures
Name Time Method Positional reliability of markers Up to 5 years Number of dropped markers up to 5 years Visibility of markers on CT and x-rays up to 5 years Marker misplacements up to 5 years Implantation-related side effects up to 5 years Usability for patient treatment up to 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Virginia Commonwealth University Massey Cancer Center
🇺🇸Richmond, Virginia, United States